PBM Reforms Signed into Law: Impact on Drug Prices & Transparency
A significant overhaul of pharmacy benefit manager (PBM) practices has been enacted into law. On Tuesday afternoon, the House of Representatives approved a spending bill containing major PBM reforms aimed at increasing price transparency for consumers and potentially lowering out-of-pocket pharmacy costs. President Donald J. Trump signed the bill into law hours later.
What the New Law Changes
The legislation, an amendment to the Consolidated Appropriations Act of 2026, fundamentally alters how PBMs are compensated within Medicare Part D. Currently, PBMs profit from manufacturer rebates and a practice called spread pricing. The new policy “delinks” PBM compensation from these sources, requiring them to receive flat administrative fees instead. This change is intended to reduce incentives for PBMs to favour higher-priced drugs.
Transparency and Data Collection
The reforms introduce new transparency requirements, enabling the centres for Medicare & Medicaid Services (CMS) to track financial relationships between PBMs, pharmacies, and drug manufacturers. Data collection will include prescription drug spending, manufacturer rebates, spread pricing arrangements, and formulary placement rationale. This increased visibility aims to shed light on how PBMs operate and negotiate drug prices.
Previous Attempts at Reform
This legislation represents a rare success in PBM reform efforts. A previous attempt to address drug pricing practices stalled in late 2024 during broader government reform negotiations. The current bill’s passage signifies a renewed focus on addressing the complexities of the pharmaceutical supply chain.
Potential Limitations and Industry Response
While the legislation is a significant step, its impact on drug prices may be limited. Industry leaders, including Cigna, UnitedHealth Group, and CVS Health, have already begun adjusting their business models to anticipate the reforms, with some committing to full rebate pass-through. However, critics suggest that PBMs may offset lost revenue through administrative fees or other pricing mechanisms.
Frequently Asked Questions
What does this bill do regarding PBM compensation?
The bill requires PBMs to receive flat administrative fees instead of profiting from manufacturer rebates and spread pricing.
What kind of data will CMS be able to track?
CMS will be able to track financial flows between PBMs and pharmacies, as well as PBM-negotiated rates with drug manufacturers, including prescription drug spending and rebate arrangements.
Has there been previous effort to reform PBM practices?
Yes, a previous effort to address drug pricing practices stalled in late 2024 amid broader government reform negotiations.
How will these changes ultimately affect the cost of prescription drugs for consumers remains to be seen.